Drying Studies of Purple Non-Sulphur Bacterial Biomass and Application as a Single-Cell Protein Feed for <i>Litopenaeus vannamei</i> by Asifa Anwar (20884229)

“…The Ameri model fitted the best in cases of 60℃ and 80℃ in all of the considered thickness of biomass, while the Midilli-Kucuk model performed better at 100℃ and 120℃ for the majority of the thicknesses (with the exception of Page model in case of 2 mm at 100℃ and 4 mm at 120℃) where temperature gradients across the biomass become more pronounced. The drying rate decreased with increasing thickness of the biomass film because more time and energy are required to remove moisture from the paste through the film to the surface. …”

Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in... by Goran Petrovski (129836)

“…The primary outcome of the study was the change in the time spent in the target in range (TIR) of 70–180 mg/dl and HbA1c from baseline (MDI + CGM, 1 week) to study phase (AHCL, 12 weeks). …”

Genetic Deletion of DNAJB3 Using CRISPR-Cas9, Produced Discordant Phenotypes by Shadi Nejat (19457212)

“…We previously showed, for the first time, impaired expression of DNAJB3 mRNA and protein in subjects with obesity, which was concomitant with increased metabolic stress. …”

Exergames versus self-regulated exercises with instruction leaflets to improve adherence during geriatric rehabilitation: a randomized controlled trial by Peter Oesch (3572426)

“…Adherence was comparable at day one (38 min. in the EG and 42 min. in the CG) and significantly higher in the CG at day 10 (54 min. in the CG while decreasing to 28 min. in the EG, <i>p</i> = 0.007, ES 0.94, 0.39–0.151). …”

Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1 by Natalie C Galles (9715361)

“…However, over the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of at least 90% coverage for all assessed vaccines in 2019.…”